NexCure Raises $19 Million in Series A Funding Led by RA Capital Management

NexCure Secures $19 Million in Series A Funding

NexCure, a Boston-based company focused on expanding access to advanced cancer therapies through outpatient clinics, has successfully raised $19 million in a Series A funding round. The funding, announced on March 6, 2026, was led by RA Capital Management, with participation from Cencora Ventures and Oncology Ventures.

Company Overview

NexCure aims to deliver compassionate and innovative care by integrating AI technology to improve treatment outcomes for cancer patients. The company operates through outpatient clinics, making advanced therapies more accessible to patients who need them. This approach is spearheaded by a team of experienced founders and executives, including Anish More, Founder and Chief Business Officer, Sophie Papa, Founder and Chief Medical Officer, and Jennifer L. Smith, CEO and Board Member.

Investors and Funding Details

The Series A funding round was led by RA Capital Management, a prominent investor known for backing healthcare and biotech innovations. Other notable investors in this round include Cencora Ventures and Oncology Ventures. This injection of capital is expected to help NexCure further its mission of providing advanced cancer treatments.

Planned Use of Funds

The newly acquired $19 million will be directed towards enhancing NexCure's service delivery capabilities and expanding its network of outpatient clinics. The company plans to invest in AI technology advancements that can further optimize patient care and treatment outcomes. Additionally, NexCure aims to increase its workforce to support these expansions and improvements.

Leadership Insights

Jennifer L. Smith, CEO of NexCure, emphasized the importance of this funding round in achieving the company’s goals, stating, "This investment will enable us to bring our innovative cancer therapies to more patients and improve their healthcare experiences."

Conclusion

With this substantial Series A funding, NexCure is well-positioned to enhance its operations and continue its work in making advanced cancer therapies more accessible. The support from investors like RA Capital Management, Cencora Ventures, and Oncology Ventures underscores the potential impact of NexCure's mission in the healthcare sector.